[90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128)

DRUG2 trials

Sponsors

Bayer, Spectrum Pharmaceuticals, Inc

Conditions

Lymphoma, FollicularNon-Hodgkin LymphomaNon-Hodgkin's Lymphoma (NHL)

Unknown Phase

A Prospective Observational Study to Evaluate the Quality of Life and the Costs in a Real Life Setting in Patients Who Are Treated With 90Y-Zevalin

CompletedNCT01164696

BayerLymphoma, Follicular, Non-Hodgkin Lymphoma

Start: 2007-08-31End: 2009-05-31Updated: 2010-08-24

Zevalin Post-marketing Surveillance in Japan

CompletedNCT01448928

Spectrum Pharmaceuticals, IncNon-Hodgkin's Lymphoma (NHL)

Start: 2008-09-30End: 2018-01-31Updated: 2021-10-01